Method
AssigneeUlifetec SAS
InventorsUlrich Bockelmann, Ismail Cissé
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of detecting and/or quantifying a RNA, particularly a tRNA, using padlock probes comprising terminal regions complementary to said RNA. The present invention also relates to methods of detecting, diagnosing and/or assessing the clinical severity of an RNA-associated disease.
Claims70
A padlock probe comprising terminal regions complementary to a tRNA, wherein a terminal region is complementary to a region of the tRNA that is associated with a pathogenic mutation.
The padlock probe according to any preceding claim, the region of the tRNA that is associated with a pathogenic mutation comprises or consists of:
- (i) a fragment of the nucleotide sequence
- (SEQ ID NO:
- 25)
- GUUAAGAUGGCAGGGCCCGGUAAUCGCAUAAAACUUAAAACUUUACAGU
- CAGAGGUUCAAUUCCUCUUCUUAACACCA,
- optionally wherein the fragment comprises nucleotide 14 of SEQ ID NO:
- 25;
- or
- (ii) a fragment of the nucleotide sequence
- (SEQ ID NO:
- 23)
- GUUAAGAUGGCAGAGCCCGGUAAUCGCAUAAAACUUAAAACUUUACAGU
- CAGAGGUUCAAUUCCUCUUCUUAACACCA,
- optionally wherein the fragment comprises nucleotide 14 of SEQ ID NO:
- 23.
The padlock probe according to any preceding claim, wherein a terminal region comprises or consist of the nucleotide sequence TTACCGGGCC (SEQ ID NO:
- 56) or TTACCGGGCT (SEQ ID NO:
- 58), or fragments thereof.
The padlock probe according to any preceding claim, wherein the terminal regions comprise or consist of the nucleotide sequences CTGCCATCTTAAC and TTACCGGGCC (SEQ ID NOs:
- 55 and 56) or CTGCCATCTTAAC and TTACCGGGCT (SEQ ID NOs:
- 57 and 58), or fragments thereof.
The padlock probe according to any preceding claim, wherein the padlock probe comprises or consists of a nucleotide sequence with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to
- (SEQ ID NO:
- 63)
- CTGCCATCTTAACTGTAGGGGAGGAGCTGACCACACTTATCATTATCTT
- CGCACAGACGTTACCGGGCC
- or
- (SEQ ID NO:
- 64)
- CTGCCATCTTAACTGGTGAGGTAAAGAACGAAGACTTCTTATCATTATC
- TACGAGCGGACGATTACCGGGCT
The padlock probe according to any preceding claim, wherein the padlock probe comprises or consists of
- (SEQ ID NO:
- 63)
- CTGCCATCTTAACTGTAGGGGAGGAGCTGACCACACTTATCATTATCTT
- CGCACAGACGTTACCGGGCC
- or
- (SEQ ID NO:
- 64)
- CTGCCATCTTAACTGGTGAGGTAAAGAACGAAGACTTCTTATCATTATC
- TACGAGCGGACGATTACCGGGCT
The padlock probe according to any preceding claim, wherein the region of the tRNA that is associated with a pathogenic mutation comprises the pathogenic mutation.
A padlock probe comprising terminal regions complementary to a tRNA, wherein a terminal region is complementary to a region of the tRNA that is associated with a modified nucleotide.
A padlock probe comprising terminal regions complementary to a tRNA comprising a 3′ ligated oligonucleotide, wherein a terminal region is complementary to a region of the tRNA that comprises at least part of the 3′ ligated oligonucleotide.
The padlock probe according to any preceding claim, wherein the tRNA is a mitochondrial tRNA (mt-tRNA).
The padlock probe according to any preceding claim, wherein the tRNA is a leucine(UUR) mt-tRNA, a lysine mt-tRNA, a methionine mt-tRNA, a tryptophan mt-tRNA, a aspartate mt-tRNA, an isoleucine mt-tRNA, a glycine mt-tRNA, an arginine mt-tRNA, a histidine mt-tRNA, a serine(AGY) mt-tRNA, a leucine(CUN) mt-tRNA, a threonine mt-tRNA, a phenylalanine mt-tRNA, a valine mt-tRNA, a glutamine mt-tRNA, an alanine mt-tRNA, an asparagine mt-tRNA, a cysteine mt-tRNA, a tyrosine mt-tRNA, a serine(UCN) mt-tRNA, a glutamate mt-tRNA, or a proline mt-tRNA.
The padlock probe according to any preceding claim, wherein the tRNA is a leucine(UUR) mt-tRNA, a lysine mt-tRNA, a histidine mt-tRNA, a leucine(CUN) mt-tRNA, a phenylalanine mt-tRNA, a valine mt-tRNA, a glutamine mt-tRNA, a serine(UCN) mt-tRNA, or a proline mt-tRNA.
The padlock probe according to any preceding claim, wherein the tRNA is a leucine(UUR) mt-tRNA or a lysine mt-tRNA, optionally wherein the tRNA is a leucine(UUR) mt-tRNA.
The padlock probe according to any preceding claim, wherein the region of the tRNA that is associated with a pathogenic mutation, associated with a modified nucleotide or comprises at least part of the 3′ ligated oligonucleotide is 5-30 nucleotides in length, optionally 5-15 nucleotides in length.
The padlock probe according to any preceding claim, wherein the terminal regions are each 5-30 nucleotides in length, optionally 5-15 nucleotides in length.
The padlock probe according to any preceding claim, wherein the terminal regions in total are 15-50 nucleotides in length, optionally 20-30 nucleotides in length.
The padlock probe according to any preceding claim, wherein the terminal regions are complementary to adjacent regions of the RNA.
The padlock probe according to any preceding claim, wherein the padlock probe is 50-200 nucleotides in length, 50-150 nucleotides in length, 50-100 nucleotides in length, or 70-100 nucleotides in length.
The padlock probe according to any preceding claim, wherein the padlock probe comprises one or more primer binding sites, optionally wherein the padlock probe comprises a forward primer site and a reverse primer site.
The padlock probe according to any preceding claim, wherein the padlock probe comprises from 5′ to 3′:
- a first terminal region;
- a first primer binding site;
- a second primer binding site;
- and a second terminal region;
- optionally wherein the first primer binding site is a forward primer site and the second primer binding site is a reverse primer binding site, or the first primer binding site is a reverse primer site and the second primer binding site is a forward primer binding site.
The padlock probe according to any preceding claim, wherein the padlock probe comprises a tag or barcode sequence.
A kit or composition comprising one or more padlock probes according to any preceding claim.
A method of detecting, diagnosing and/or assessing the clinical severity of a tRNA-associated disease comprising:
- (a) determining the concentration of wild-type tRNAs (cwt);
- (b) determining the concentration of mutant or aberrantly-modified tRNAs (cmut);
- and
- (c) calculating the percentage tRNA mutation load or aberrant-modification load, cmut/(cwt+cmut).
Use of a padlock probe for detecting, diagnosing and/or assessing the clinical severity of a tRNA-associated disease.
Use of a padlock probe for detecting and/or quantifying tRNA amino-acid charging.
Dependencies are inferred from the claim text.